Tyra Biosciences is under investigation by Pomerantz LLP for potential securities fraud following the release of Phase 2 trial results for its cancer drug dabogratinib. The trial showed a favorable safety profile but reported serious adverse events in 14% and 9% of patients at different doses. After the announcement, Tyra's stock price fell sharply by 17.66%. The investigation will determine if the company or its officers engaged in unlawful practices. Investors affected are advised to contact the law firm for potential class action participation.
Tyra Biosciences is currently under investigation for potential securities fraud following its Phase 2 cancer drug trial results. For readers following the health sector, here is Pluang's market snapshot as of Oct 08, 2026 21:12 WIB: out of 128 priced US health-sector stocks, 17 rose and 111 fell. Notable movers include Guardant Health Inc. (GH) at USD 162.30 with a 3.58% decline, Citius Pharmaceuticals Inc. (CTXR) at USD 0.49 with a 3.58% drop and a typical hold time of 16 days on Pluang, and SELLAS Life Sciences Group Inc. (SLS) at USD 10.91 down 3.54%.
Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portf...
Seaport Global increased Shopify's price target from $175 to $180, reflecting an 8.3% upside from the current price of $166.16. Shopify's shares have surged 80% since May, pushing its market value above $205 billion. The rally is driven by a strategi...
Tesco reported earnings per share of $0.69, beating estimates of $0.64, despite revenue falling short at $44.60 billion versus $49.60 billion expected. The UK supermarket raised its full-year adjusted operating profit forecast to £3.15-3.30 billion, ...
CIQ has released Fuzzball 4.3, a platform that enables enterprises to deploy validated open-weight AI models and agents on their existing GPU infrastructure with a single command. This update simplifies operationalizing AI by automatically connecting...
As of September 30, 2026, Societe Generale's share capital consists of 739,264,232 shares with a total of 821,169,560 voting rights. The bank highlights its strong global presence with 110,000 employees serving 27 million clients across 58 countries....
